Erythropoietin (Epo) is an important regulator of erythropoiesis and stimulates the proliferation of early erythroid precursors as well as the differentiation of late erythroid precursors of the erythroid lineage. However, recent studies have indicated that Epo also has angiogenic properties and plays an important role in the oestrogendependent cyclical angiogenesis within the mouse uterus. It was therefore postulated that Epo may be an important angiogenic factor in endometriosis. In order to address this hypothesis the concentration of Epo in peritoneal fluid (PF) was determined in patients with or without endometriosis. PF was collected from patients with endometriosis (n ⍧ 42) or without endometriosis (n ⍧ 18). Detectable concentrations of Epo were found in all PF samples analysed. The concentration of Epo in PF from patients with endometriosis was significantly higher than that in the control group (13.1 ⍨ 1.2 mIU/ml versus 7.2 ⍨ 0.7 mIU/ml, mean ⍨ SE respectively, P < 0.01). Furthermore, in patients with endometriosis the Epo concentrations in PF from patients with stage I disease (n ⍧ 17, 16.6 ⍨ 3.0 mIU/ml) were significantly higher than those with stage II (n ⍧ 8, 10.7 ⍨ 1.2 mIU/ml, P < 0.03), III (n ⍧ 13, 8.4 ⍨ 1.0 mIU/ml, P < 0.01), IV disease (n ⍧ 7, 7.5 ⍨ 1.0 mIU/ml, P < 0.01). These data suggest that Epo may play a role in the pathogenesis of endometriosis particularly in the initiation of the disease.
Introduction
factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), IL-6 and IL-8, which were formerly thought Endometriosis is a common gynaecological disorder of to be predominantly specific for the haematopoietic cells, are unknown aetiology and accounts for infertility and pelvic pain also capable of affecting certain endothelial cell functions in 10-15% of women of reproductive age. Angiogenesis is including angiogenesis (Bikfalvi and Han, 1994) . Erythropoiethe formation of new capillaries from pre-existing vessels and tin (Epo) is a key factor in the regulation of erythropoiesis it is now apparent that this process plays an important role in and stimulates the proliferation of early erythroid precursors the pathogenesis of this condition (Healy et al., 1998) . and the differentiation of late erythroid precursors of the Studies have demonstrated that angiogenic factors may be erythroid lineage (Krantz, 1991; Jelkmann, 1992) . However, localized to endometriotic tissues and were also found to important recent studies have demonstrated the angiogenic be increased in the peritoneal fluid (PF) of women with potential of Epo (Carlini et al., 1995; Yasuda et al., 1998 ; endometriosis (Oosterlynck et al., 1993; Ferriani et al., 1993; Masuda et al., 1999; Ribatti et al., 1999) . In addition, the Epo Ryan et al., 1995; McLaren et al., receptor has been demonstrated in endothelial cells both in vitro 1996a,b; Shifren et al., 1996; Donnez et al., 1998; Gazvani and in vivo (Anagnostou et al., 1994) . Furthermore, Epo et al., 1998; Iwabe et al., 1998; Osuga et al., 1999) . The stimulation of endothelial cells may elicit an angiogenic release of angiogenic factors into the peritoneal cavity may response in vitro and in vivo (Carlini et al., 1995; Ribatti et al. , well stimulate increased neovascularization of endometriotic 1999). Lastly, physiological angiogenesis occurs within the tissues (Ramey and Archer, 1993; Koninckx et al., 1998) .
female reproductive organs of the adult and a recent study Therefore, the detection and evaluation of potent angiogenic demonstrated that Epo is involved in the oestrogen-dependent factors in endometriosis is important and could potentially cyclical angiogenesis occurring within the mouse uterus lead to the design of novel therapeutic strategies aimed at both (Yasuda et al., 1998; Masuda et al., 1999) . preventing and treating endometriosis.
It was therefore postulated that Epo is one of the angiogenic Recent studies have indicated that several cytokines and factors involved in endometriosis. This hypothesis was addressed by initially determining if Epo was present in PF interleukins (IL) including granulocyte colony stimulating Patients undergoing laparoscopic surgery for infertility or investigation of pelvic pain or a pelvic mass were recruited for the study. All
Results
patients had a normal menstrual cycle and had received no hormonal treatment during the 6 month period prior to the surgery. PF and a
Erythropoietin was detectable in all samples of PF analysed.
serum sample were collected during the laparoscopy. Fluid was However, the concentration of EPO in the PF of patients with aspirated from the posterior cul-de-sac immediately after the insertion endometriosis was significantly higher than that in the control of the trocar. The volume of peritoneal fluid was noted. Samples group (13.1 Ϯ 1.2 versus 7.2 Ϯ 0.7 mIU/ml respectively, were centrifuged at 800 g for 10 min at 4°C in order to remove cells P Ͻ 0.01, Table I ). Furthermore, Epo concentrations in PF and debris and the supernatants were stored at -80°C until analysis.
from patients with stage I disease (16.6 Ϯ 3.0 mIU/ml)
Operative findings were recorded regarding the presence of endowere significantly higher than those with stage II, III, IV metriosis and its location, extent and degree. The degree of endoendometriosis and those in the control group (10.7 Ϯ 1.2 mIU/ metriosis was scored according to the latest revision of the American ml, P Ͻ 0.03; 8.4 Ϯ 1.0 mIU/ml, P Ͻ 0.01; 7.5 Ϯ 1.0 mIU/ Society for Reproductive Medicine classification (American Society ml, P Ͻ 0.01; 7.2 Ϯ 0.7 mIU/ml, P Ͻ 0.001 respectively, for Reproductive Medicine, 1997), and biopsy specimens were taken Figure 1 ). were significantly higher than those with black lesions only from 18 women with no visible evidence of pelvic pathology served (16.3 Ϯ 2.7 versus 7.3 Ϯ 1.6 mIU/ml respectively, P Ͻ 0.03).
as controls. There were no significant differences in the clinical Epo concentrations in PF from patients with and without characteristics between the patients with or without endometriosis endometriosis were not correlated with the phase of the (Table I ). All peritoneal fluid and serum samples were obtained with menstrual cycle (Table I) . Epo concentrations in PF of patients the patient's full informed consent whilst the human research board with endometriosis were significantly higher than those in the of the ethical committee of Tohoku University School of Medicine paired serum (13.1 Ϯ 1.2 versus 8.4 Ϯ 0.6 mIU/ml respectively, approved the research protocol. Epo concentrations in peritoneal fluid and serum were measured P Ͻ 0.01). There was no correlation between the paired serum using a commercially available enzyme immunoassay kit (Immunoand PF Epo concentrations from patients with endometriosis.
eritto, Toyobo, Tokyo, Japan) which had a detection limit of 0.3 mIU/ ml. The intra-assay and interassay coefficients of variation were 5.9 and Ͻ10% respectively. Epo concentrations in duplicate PF samples (Donnez et al., 1992; Nisolle et al., 1993 Nisolle et al., , 1997 Nisolle and Donnez, 1997; Donnez et al., 1998; Matsuzaki et al., 1998) . Although our sample size was too small, the present findings suggest that PF Epo concentrations from patients with red lesions only may be higher than those with black lesions only. Further studies are needed to find a relationship between PF Epo concentrations and the presence of red peritoneal lesions only (Calhaz-Jorge et al., 2000) . The angiogenic response of the chick embryo chorioallantoic membrane blood vessels to Epo is comparable with that elicited by the prototypic angiogenic cytokine basic fibroblast growth factor (Ribatti et al., 1999) . Fibroblast growth factor is one of the potent angiogenic factors in endometriosis (Ferriani et al. 1993) . Several other angiogenic factors are also considered to be involved in the pathogenesis of endometriosis (Oosterlynck et al., 1993 Ryan et al., 1995; McLaren et al., 1996a,b; Shifren et al., 1996; Donnez et al., 1998; Gazvani et al., 1998; Iwabe et al., 1998; Osuga et al., 1999) . Therefore, the relative strength of the action of Epo should be investigated in endometriotic tissues.
The cellular source of origin of PF Epo remains to be investigated. The major site of erythropoietin production in the adult is the kidney although extrarenal sites of Epo production may include bone marrow macrophages (Vogt et al., 1989), early colony-forming cells (Hermine et al., 1991) , of 18 patients without endometriosis (control) and 42 patients with brain astrocytes (Masuda et al., 1994) and trophoblast cells endometriosis at various stages (stage I: n ϭ 14, stage II: n ϭ 8, stage III: n ϭ 13, stage IV: n ϭ 7). The circle represents the (Conrad et al., 1996) . Diffusion rates between PF and the erythropoietin concentration, and the horizontal line represents the blood stream decreases with increasing molecular weight to median value. Epo concentrations in PF from patients with stage I become extremely slow for molecules with a molecular weight were significantly higher than those with stage II, stage III, stage Ͼ100 kDa (Dunselman et al., 1988) . Prolactin (molecular IV and without endometriosis (control) (P Ͻ 0.03, P Ͻ 0.01, weight: 20 kDa) and albumin (molecular weight: 60 kDa) P Ͻ 0.01 and P Ͻ 0.001 respectively). C: control.
concentrations are 67% of those in serum (Koninckx et al., 1980; Pattinson et al., 1981) . The molecular weight of Epo is 1998). Furthermore, the concentration of IL-8 in PF was significantly correlated with the extent of active endometriosis approximately 30 kDa (Tilbrook and Klinken, 1999) . If the origin of the PF Epo is from the serum, theoretically, Epo (Iwabe et al., 1998) . Thus, it may be speculated that IL-8 may be an important factor in the initiation of the disease since concentrations in the paired serum should be higher than those in PF. However, Epo concentrations of PF were significantly other potent angiogenic factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) higher than those of the paired serum. In addition, no correlations were detected between the paired serum and PF Epo have been reported to be elevated in the late stages of endometriosis rather than in the early stage (McLaren et al. concentrations. Therefore, extrarenal sites of Epo production should be considered as a potential source. A recent in-vitro 1996a; Osuga et al., 1999) . Superficial endometrial implants may be regulated by PF factors, whereas deep endometriosis study demonstrated that the mouse uterus expressed Epo mRNA and produced Epo protein in an oestrogen dependent and cystic ovarian endometriosis may be more influenced by blood or ovarian factors (Koninckx et al., 1998) . In the present manner (Yasuda et al., 1998; Masuda et al., 1999) . This suggests that refluxed endometrial tissues may be direct study, it was demonstrated that Epo concentrations in PF from patients with stage I disease were significantly higher than candidates for a source of Epo production and secretion into PF. However, in the present study differences in PF Epo those with stage II, III or IV disease. All patients with stage I disease recruited in the present study included only superficial concentrations according to disease severity were detected. In addition, refluxed endometrial tissues are not specific to patients endometrial lesions. Thus, it was postulated that Epo in addition to IL-8 may play a role in the initiation phase of the disease.
with endometriosis. Therefore, it is likely that endometrial tissues are not the sole source of Epo in PF. Endometriosis is Peritoneal endometriotic lesions can be further classified into three lesion types: red, black and white, according to their associated with increased concentrations of activated macrophages, which may produce many cytokines, growth factors macroscopic appearance (American Society for Reproductive Medicine, 1997; Nisolle and Donnez, 1997) . It is postulated and angiogenic factors (Koninckx et al., 1998) . Indeed, it has been demonstrated that activated macrophages are a major that these three types of peritoneal lesions may represent Koninckx, P.R., De Moor, P. and Brosens, I.A. (1980) Diagnosis of the source of VEGF in endometriosis (McLaren et al., 1996b) In conclusion, this study suggests that Epo may play a role Masuda, S., Okano, M., Yamagishi, K. et al. (1994) A novel site of in the pathogenesis of endometriosis, particularly during the erythropoietin production. J. Biol. Chem., 269, 19488-19493. early stages of the disease. Further studies to clarify a role of 
